External high-voltage radiotherapy of carcinoma of the prostate and the regional lymph nodes.
External high-voltage radiotherapy of carcinoma of the prostate and the field of regional lymphatic spread leads to regression of the tumour in over half the cases. The definite response to radiotherapy does not seem to be related either to the degree of histological differentiation or to the palpable extent of the tumour in the pelvis and is not always seen until at least 6 months from the end of treatment. Radiotherapy has a good palliative effect. Oestrogens need not be administered during irradiation and subsequently as long as no disease activity is detectable.
D002454:Cell Differentiation; D004967:Estrogens / Q000627:therapeutic use; D006801:Humans; D008198:Lymph Nodes; D008297:Male; D011471:Prostatic Neoplasms / Q000188:drug therapy / Q000532:radiotherapy*; D011882:Radiotherapy, High-Energy; D013997:Time Factors
D004967:Estrogens